GeneHealth - Your precision medicine

Choroid Plexus Cancer

Disease Details

Family Health Simplified

Buy Membership

Description: Choroid plexus cancer is a rare, malignant tumor that occurs in the choroid plexus of the brain, primarily affecting children and causing increased intracranial pressure and hydrocephalus.
Type: Choroid plexus cancer, specifically referring to choroid plexus carcinoma, is a rare type of cancer that arises in the choroid plexus tissue within the brain's ventricles. This type of cancer is typically sporadic, meaning it occurs by chance and is not usually inherited. However, some cases can be linked to genetic syndromes such as Li-Fraumeni syndrome, which is inherited in an autosomal dominant pattern.
Signs And Symptoms: Choroid plexus cancer often presents with symptoms caused by increased intracranial pressure due to the tumor's location in the brain. Common signs and symptoms include:

- Headaches
- Nausea and vomiting
- Seizures
- Lethargy or fatigue
- Balance and coordination difficulties
- Vision problems
- Irritability, particularly in infants
- Increased head size in infants (hydrocephalus)
- Bulging fontanel (soft spot on the head in infants)

Given the nonspecific nature of these symptoms, it is essential to perform a thorough medical evaluation for an accurate diagnosis.
Prognosis: Choroid plexus cancer, specifically choroid plexus carcinoma, is a rare malignancy primarily occurring in children. Prognosis varies based on factors such as age, tumor location, extent of surgical resection, and response to therapy.

For choroid plexus carcinoma:
- **Children** generally have a better prognosis than adults.
- **Complete surgical resection** significantly improves outcomes.
- Adjuvant **chemotherapy and radiation** may be used, though their impact varies.
- **Survival rates** can vary widely, with 5-year survival rates reported between 40% to 60% in some studies.

Follow-up care is essential for managing potential recurrences or complications.
Onset: Choroid plexus carcinoma is a rare type of brain tumor that occurs primarily in children but can also affect adults. Its onset involves the development of cancerous cells in the choroid plexus, which is part of the brain responsible for producing cerebrospinal fluid. The exact cause of this cancer is not well understood, but genetic mutations may play a role. Early symptoms may include signs of increased intracranial pressure such as headaches, nausea, vomiting, and changes in behavior or cognitive function. Early diagnosis and treatment are critical for better outcomes.
Prevalence: Choroid plexus carcinoma is a rare type of brain cancer that primarily affects children. Due to its rarity, specific prevalence data is limited, but it is estimated to account for less than 1% of all brain tumors.
Epidemiology: Choroid plexus cancer, also known as choroid plexus carcinoma (CPC), is a rare malignant brain tumor originating from the choroid plexus tissue, which produces cerebrospinal fluid. It primarily affects children, with the majority of cases occurring in those under 2 years of age. Incidence rates are estimated to be about 0.3 cases per million annually. CPC can also occur in adults but is exceedingly rare in this population. Regular monitoring and early diagnosis can improve treatment outcomes, emphasizing the importance of awareness and specialized medical care.
Intractability: Choroid plexus cancer, particularly choroid plexus carcinoma, is considered a challenging disease to treat. It can be intractable due to its aggressive nature and tendency to spread within the central nervous system. Treatment options typically include surgery, chemotherapy, and radiation therapy, but outcomes can be variable and often depend on factors such as the patient's age and the tumor's location and resectability.
Disease Severity: Choroid plexus cancer, a rare type of brain tumor that affects the choroid plexus in the brain, can vary in severity. Its severity largely depends on factors like the tumor's size, location, and whether it has spread to other parts of the brain or body. Given its potential to cause significant neurological symptoms and the difficulty in treatment, it is generally considered a serious condition.
Healthcare Professionals: Disease Ontology ID - DOID:3540
Pathophysiology: Choroid plexus cancer, specifically choroid plexus carcinoma, is a rare and malignant tumor originating from the choroid plexus tissue in the brain. The choroid plexus is responsible for producing cerebrospinal fluid (CSF). The pathophysiology involves uncontrolled proliferation of epithelial cells in the choroid plexus, leading to the formation of a tumor. This can obstruct CSF flow, resulting in increased intracranial pressure and hydrocephalus. Mutations in genes like TP53 have been implicated. Symptoms often include headaches, nausea, vomiting, and neurological deficits due to the tumor's pressure effects on adjacent brain structures.
Carrier Status: Carrier status is not typically applicable to choroid plexus cancer. Choroid plexus tumors are generally not related to inherited mutations where carrier status applies. These tumors can occur sporadically or, in rare cases, be associated with genetic conditions such as Li-Fraumeni syndrome.
Mechanism: Choroid plexus cancer, also known as choroid plexus carcinoma (CPC), is a rare, malignant tumor that affects the choroid plexus of the brain, which is responsible for producing cerebrospinal fluid. The exact mechanism of CPC development is not fully understood, but several molecular mechanisms have been implicated.

1. **Genetic Mutations**: Mutations in key genes are often found in CPCs. For example, TP53 mutations, which lead to the loss of function of the p53 protein, are common and result in the inability to regulate cell cycle and apoptosis, allowing uncontrolled cell growth.

2. **Chromosomal Aberrations**: CPCs frequently exhibit chromosomal abnormalities, such as gains and losses of whole chromosomes or large chromosomal regions. These can lead to oncogene activation or tumor suppressor gene inactivation.

3. **Signaling Pathways**: Abnormal activation of signaling pathways such as the Wnt/β-catenin pathway, Hedgehog signaling, and Notch signaling can also contribute to CPC development. Dysregulation in these pathways promotes proliferation, survival, and invasion of cancer cells.

4. **Epigenetic Changes**: Alterations in DNA methylation and histone modification patterns can affect gene expression without changing the DNA sequence. Such epigenetic changes are known to play a role in the development and progression of CPC.

5. **Inflammation and Microenvironment**: Chronic inflammation and changes in the tumor microenvironment, such as hypoxia and interactions with surrounding cells, can contribute to tumor growth and resistance to therapy.

Understanding these molecular mechanisms is crucial for developing targeted therapies and improving outcomes for patients with choroid plexus carcinoma.
Treatment: Choroid plexus carcinoma, a rare and malignant tumor of the brain, typically requires a multidisciplinary treatment approach. The primary treatment usually involves surgical resection to remove as much of the tumor as possible. This may be followed by radiation therapy to target residual cancer cells. Chemotherapy may also be employed, particularly in cases where complete surgical removal is not feasible or if the cancer has spread. The treatment plan is often individualized based on the patient's age, overall health, and the specific characteristics of the tumor.
Compassionate Use Treatment: Choroid plexus tumors are rare and typically categorized into papillomas (benign) and carcinomas (malignant). For choroid plexus carcinomas, compassionate use treatment and off-label or experimental treatments might be considered due to the aggressive nature of the disease and limited standard treatment options.

1. **Compassionate Use Treatment**: This route is considered for patients who have exhausted all standard treatments. Potential drugs or interventions under compassionate use might be investigational agents that are still in clinical trials but have shown promise in treating similar tumors or central nervous system malignancies.

2. **Off-Label Treatments**: Certain chemotherapy agents, radiation therapy techniques, and targeted therapies used off-label for choroid plexus carcinoma include:
- **Temozolomide**: An oral chemotherapy drug often used for gliomas.
- **Bevacizumab**: A monoclonal antibody targeting VEGF, used in various cancers to inhibit angiogenesis.
- **Etoposide** and **Carboplatin**: Chemotherapy agents sometimes applied in a pediatric oncology setting.

3. **Experimental Treatments**: These typically involve enrolling in a clinical trial. Current experimental treatments might include:
- **Immunotherapy**: Such as checkpoint inhibitors (e.g., pembrolizumab) which help the immune system recognize and attack cancer cells.
- **Targeted Therapy**: Genomic profiling of the tumor might help identify specific mutations that can be targeted by novel agents.
- **Gene Therapy**: Experimental interventions that aim to correct or modify the genetic anomalies driving the cancer.

Patients considering these options should consult with their oncologist to evaluate eligibility, potential benefits, and risks.
Lifestyle Recommendations: Choroid plexus cancer is a rare type of brain tumor that primarily affects the choroid plexus cells, which produce cerebrospinal fluid. While specific lifestyle recommendations tailored for choroid plexus cancer may not be widely established due to its rarity, general recommendations for cancer patients can be helpful:

1. **Nutrition**: Maintain a balanced diet rich in fruits, vegetables, whole grains, and lean proteins to support overall health and immune function.
2. **Physical Activity**: Engage in regular, moderate physical activity as tolerated, such as walking or gentle yoga, to help maintain physical strength and reduce fatigue.
3. **Rest**: Ensure adequate sleep and rest periods to help the body recover from treatments and cope with symptoms.
4. **Hydration**: Stay well-hydrated by drinking plenty of water throughout the day.
5. **Stress Management**: Practice stress-reduction techniques such as meditation, deep breathing exercises, or gentle hobbies to help manage anxiety and emotional strain.
6. **Follow Medical Advice**: Adhere to treatment plans and follow-up appointments as prescribed by healthcare providers.
7. **Support Networks**: Engage with support groups, family, and friends to maintain emotional well-being and receive encouragement.

For personalized recommendations, always consult with healthcare providers familiar with your specific case.
Medication: There is no specific medication solely for choroid plexus cancer. Treatment typically involves a combination of surgery to remove the tumor, followed by radiation therapy or chemotherapy, particularly if the tumor is malignant or cannot be entirely removed surgically. Common chemotherapeutic agents used may include cisplatin, etoposide, cyclophosphamide, and vincristine. Specific treatment protocols can vary depending on the patient's age, the cancer's grade, and the overall health of the patient. Always consult with a specialized oncologist to determine the most appropriate treatment plan.
Repurposable Drugs: Choroid plexus cancer, which includes malignancies of the choroid plexus such as choroid plexus papillomas and carcinomas, can potentially benefit from repurposed drugs. Repurposed drugs are existing medications approved for other conditions that show efficacy against different diseases, including cancers. Some examples include:

1. **Valproic Acid**: Originally an anticonvulsant, it has shown potential in tumor suppression due to its histone deacetylase inhibitory effects.
2. **Bevacizumab**: An anti-VEGF antibody initially used for various cancers and ocular diseases, it may help in managing choroid plexus tumors by inhibiting blood vessel growth.
3. **Vorinostat**: A histone deacetylase inhibitor originally used for cutaneous T-cell lymphoma, has demonstrated antitumor activity in various cancers.
4. **Temozolomide**: An alkylating agent principally used for gliomas and other brain tumors, it has shown some efficacy in choroid plexus carcinomas.

Though the potential for these drugs exists, the treatment plan should always be discussed with and managed by a healthcare professional specializing in oncology.
Metabolites: Choroid plexus carcinoma is a rare type of cancer that occurs in the choroid plexus of the brain. Regarding its metabolites, specific biomarkers and metabolic profiles for this cancer type are not well-documented in current clinical research. Generally, cancer metabolism can involve alterations in common metabolites such as glucose, lactate, and various amino acids, reflecting the increased metabolic demands of rapidly proliferating tumor cells. However, precise metabolites specific to choroid plexus carcinoma would require more detailed research and case-specific studies.
Nutraceuticals: There isn't sufficient evidence to suggest that nutraceuticals—food-derived products with potential health benefits—can effectively treat or manage choroid plexus cancer. This rare brain tumor primarily affects children, and its treatment typically involves a combination of surgery, chemotherapy, and sometimes radiation therapy. Nutraceuticals have not been scientifically validated as a treatment option for choroid plexus carcinoma, and any use of such products should be discussed with a healthcare professional.
Peptides: Choroid plexus cancer, specifically choroid plexus carcinoma, is a rare malignant tumor that arises in the choroid plexus of the brain. Peptides and nanoparticles (nanotechnology) represent areas of interest in its treatment.

**Peptides:**
Peptides, as therapeutic agents, have shown promise due to their ability to target specific molecular pathways involved in cancer growth and metastasis. In the case of choroid plexus carcinoma, peptide-based therapies might be explored for their potential to target tumor-specific antigens or to modulate the immune response against cancer cells.

**Nanotechnology:**
Nanotechnology involves using nanoparticles to improve the delivery of drugs to cancer cells, enhancing the effectiveness of treatments while reducing side effects. For choroid plexus carcinoma, nanoparticles can be engineered to cross the blood-brain barrier and deliver chemotherapeutic agents or other therapeutic compounds directly to the tumor site, potentially improving outcomes.

Research in these areas is ongoing, and while promising, these methods are still largely in experimental stages for this specific type of cancer.